Boardroom Alpha
Start trial
10-Q primary document
PRGO · Quarterly Report (Form 10-Q) · Filed November 5, 2025

Perrigo Co PLC — 10-Q exhibit

cy25q310qex22.htm
Perrigo Co PLC on Boardroom Alpha
Document

Exhibit 22

Subsidiary Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant

As of September 27, 2025, the obligors under (i) the 5.300% Notes due 2043 issued by the Company (the “Company Notes”) consisted of the subsidiaries listed in the following table and (ii) the 4.900% Notes due 2030, the 5.375% Euro Notes due 2032, the 6.125% USD Notes due 2032, and the 4.900% Notes due 2044 issued by Perrigo Finance Unlimited Company (collectively, the “Perrigo Finance Notes”) consisted of the Company, as a guarantor, and its subsidiaries listed in the following table.

Name of EntityObligor Type (Company Notes)Obligor Type (Perrigo Finance Notes)
Athena Neurosciences, LLCGuarantorGuarantor
Chefaro Ireland Designated Activity CompanyGuarantorGuarantor
Elan Pharmaceuticals, LLCGuarantorGuarantor
Galpharm Healthcare LimitedGuarantorGuarantor
Galpharm International LimitedGuarantorGuarantor
Gr8ness, LLCGuarantorGuarantor
L. Perrigo CompanyGuarantorGuarantor
Medgenix Benelux NVGuarantorGuarantor
OCE-BIO BVGuarantorGuarantor
Omega Pharma Innovation & Development NVGuarantorGuarantor
Omega Pharma International NVGuarantorGuarantor
Omega Pharma LimitedGuarantorGuarantor
Omega Pharma Trading NVGuarantorGuarantor
Omega Teknika Designated Activity Company
GuarantorGuarantor
PBM Canada Holdings, LLCGuarantorGuarantor
PBM Nutritionals, LLCGuarantorGuarantor
PBM Products, LLCGuarantorGuarantor
Perrigo Americas Holdings, IncGuarantorGuarantor
Perrigo Belgium NVGuarantorGuarantor
Perrigo Capital NVGuarantorGuarantor
Perrigo CompanyGuarantorGuarantor
Perrigo Company PlcIssuerGuarantor
Perrigo Corporation Designated Activity CompanyGuarantorGuarantor
Perrigo Diabetes Care, LLCGuarantorGuarantor
Perrigo Direct, Inc.GuarantorGuarantor
Perrigo Europe Invest NVGuarantorGuarantor
Perrigo Finance (US) LLCGuarantorGuarantor
Perrigo Finance Unlimited CompanyGuarantorIssuer
Perrigo Florida, Inc.GuarantorGuarantor
Perrigo Holding NVGuarantorGuarantor
Perrigo Holdings Unlimited CompanyGuarantorGuarantor
Perrigo International Finance Designated Activity CompanyGuarantorGuarantor
Perrigo International Holdings II, LLCGuarantorGuarantor
Perrigo International Holdings, LLCGuarantorGuarantor
Perrigo International, LLCGuarantorGuarantor


Perrigo Investments, LLCGuarantorGuarantor
Perrigo Ireland 1 Designated Activity CompanyGuarantorGuarantor
Perrigo Ireland 10 Unlimited CompanyGuarantorGuarantor
Perrigo Ireland 13 Designated Activity CompanyGuarantorGuarantor
Perrigo Ireland 2 Designated Activity CompanyGuarantorGuarantor
Perrigo Ireland 4 Unlimited CompanyGuarantorGuarantor
Perrigo Ireland 9 Unlimited Company
GuarantorGuarantor
Perrigo Management CompanyGuarantorGuarantor
Perrigo Mexico Investment Holdings, LLCGuarantorGuarantor
Perrigo New York, Inc.GuarantorGuarantor
Perrigo Pharma International Designated Activity CompanyGuarantorGuarantor
Perrigo Pharma LimitedGuarantorGuarantor
Perrigo Research & Development CompanyGuarantorGuarantor
Perrigo Sales CorporationGuarantorGuarantor
Perrigo Science One Designated Activity Company
GuarantorGuarantor
Perrigo Supply Chain International Designated Activity CompanyGuarantorGuarantor
Perrigo UK Acquisition LimitedGuarantorGuarantor
PMI Branded Pharmaceuticals, Inc.GuarantorGuarantor
Ranir Global Holdings, LLCGuarantorGuarantor
Ranir (Holdings) LimitedGuarantorGuarantor
Ranir, LLCGuarantorGuarantor
Wrafton Laboratories LimitedGuarantorGuarantor

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer